Enabling patient specific medicines using 3D printing in hospitals and pharmacies

Project Information

PMed

Grant agreement ID: 190157849

DOI

10.3030/190157849

Project closed

EC signature date 23 August 2023

Start date 1 September 2023

End date 31 August 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 542 500,00

EU contribution

€ 2 479 750,00

Coordinated by

CURIFYLABS OY
Finland

Periodic Reporting for period 2 - PMed (Enabling patient specific medicines using 3D printing in hospitals and pharmacies)

Reporting period: 2024-09-01 to 2025-08-31

Summary of the context and overall objectives of the project

Uniform drug treatments are not always the best option for treating some patient populations – including children and the elderly. The industry now has extensive knowledge on the benefits of personalized medicines that take the age, metabolic and genetic differences of patients into account. However, until now there has not been a practical manufacturing solution to put this knowledge into widescale use. CurifyLabs has created a technology called PharmaKit to make high quality personalized medicines available on site in the pharmacies through advanced automation technology inspired by 3D printing and bring industry level standards to mass customisation of medicines. In this project we have established a standard process for developing compatible formulations and quality control solutions for the PharmaKit technology. This has made PharmaKit scalable across different therapeutic areas.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During the project, six new excipient premixes were created, enabling printable formulations for fifty new APIs and exceeding initial targets. A standardized development process was established, reducing formulation lead times from several months to around one to two months, and more than 70 validated formulations are now available in the library.

Integrated quality control tools were introduced, including a precision weighing scale for 100% in-process verification and prototypes of near-infrared spectroscopy models for blend uniformity, providing automated and reliable Quality Control (QC). The Curify 2.0 platform was finalized and deployed on Google Cloud, supporting real-time monitoring, data analysis, and remote management of the PharmaPrinter.

New user interfaces, electronic signatures, audit trails, and advanced security solutions were also implemented. Importantly, the technology platform achieved ISO 13485 certification in June 2024, confirming its readiness for clinical use. Together these achievements establish a robust, certified system for safe and automated manufacturing of personalized medicines in pharmacies and hospitals.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The development of new excipient premixes marks a significant step forward for personalized compounding. Building on traditional excipient bases, the project delivered premixes with enhanced stability, solubility, and compatibility, validated across a wide range of APIs. More than seventy formulations were created using the standardized development process, cutting development time by more than half and enabling scalable expansion of individualized therapy options. This library, coupled with validated QC and stability protocols, provides a unique foundation for safe, rapid deployment of new patient-specific treatments.

Precision-scale integration within the PharmaPrinter has set a new benchmark for in-process control, ensuring 100% weight verification of each printed dose. Combined with the introduction of spectroscopic QC methods, such as validated NIR models for blend uniformity, the technology moves quality control from a manual, retrospective step into an automated, integrated part of the manufacturing process. This degree of assurance directly addresses regulatory expectations while providing confidence for pharmacists and healthcare providers.

Cloud integration via the Curify 2.0 platform advances the field beyond current compounding practice. Real-time connectivity supports centralized monitoring of devices, remote updates, and data-driven optimization of production. The platform has also been equipped with electronic signatures, audit trails, and role-based access to ensure compliance with Annex 11 and 21 CFR Part 11. Together, these features enable scalable, compliant, and efficient operations across multiple sites, while strengthening trust with regulators and healthcare systems.

The award of ISO 13485 certification in June 2024 confirms that the PharmaKit platform is not only technologically advanced but also built to international medical device standards. This achievement paves the way for wider clinical adoption and international market entry, demonstrating that automated, decentralized manufacturing of personalized medicines can be implemented in a regulated environment.

Looking ahead, the results achieved open new opportunities but also highlight key needs: continued development of spectroscopic QC models for additional APIs, expansion of cloud-based integrations with hospital information systems, and demonstration projects with healthcare providers to accelerate adoption. Equally, access to supportive regulatory frameworks, sustainable financing for scale-up, and strong IP protection will be critical to ensure broad uptake and long-term success.

curifylabs-logo.png